NO882218L - Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer. - Google Patents

Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.

Info

Publication number: NO882218L
Authority: NO; Norway
Prior art keywords: hmg; phosphorus; procedure; preparation; coa reductase
Prior art date: 1987-05-22

Application number

NO882218A

Other languages

English (en)

Norwegian (no)

Other versions

NO882218D0 (no

Inventor

Donald Steven Karanewsky

Scott Adams Biller

Eric Michael Gordon

Original Assignee

Squibb & Sons Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-05-22

Filing date

1988-05-20

Publication date

1988-11-23

1988-05-20 Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc

1988-05-20 Publication of NO882218D0 publication Critical patent/NO882218D0/no

1988-11-23 Publication of NO882218L publication Critical patent/NO882218L/no

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 title 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
229910052698 phosphorus Inorganic materials 0.000 title 1
239000011574 phosphorus Substances 0.000 title 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/36—Amides thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)

NO882218A 1987-05-22 1988-05-20 Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer. NO882218L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5328187A	1987-05-22	1987-05-22
US10968087A	1987-10-19	1987-10-19

Publications (2)

Publication Number	Publication Date
NO882218D0 NO882218D0 (no)	1988-05-20
NO882218L true NO882218L (no)	1988-11-23

Family

ID=26731667

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO882218A NO882218L (no)	1987-05-22	1988-05-20	Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.

Country Status (24)

Country	Link
JP (1)	JP2680347B2 (fr)
KR (1)	KR880013958A (fr)
CN (1)	CN88103091A (fr)
AU (1)	AU610591B2 (fr)
BE (1)	BE1004193A3 (fr)
CH (1)	CH676984A5 (fr)
DE (1)	DE3817375C2 (fr)
DK (1)	DK277488A (fr)
ES (1)	ES2009918A6 (fr)
FI (1)	FI89493C (fr)
FR (1)	FR2615508B1 (fr)
GB (1)	GB2205837B (fr)
GR (1)	GR1000959B (fr)
HU (1)	HU205125B (fr)
IE (2)	IE63760B1 (fr)
IL (1)	IL86464A (fr)
IT (1)	IT1217685B (fr)
NL (1)	NL8801330A (fr)
NO (1)	NO882218L (fr)
NZ (1)	NZ224733A (fr)
PH (1)	PH25350A (fr)
PL (1)	PL154877B1 (fr)
PT (1)	PT87539B (fr)
SE (1)	SE503210C2 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2009919A6 (es) *	1987-05-22	1989-10-16	Squibb & Sons Inc	Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo y nuevos compuestos intermedios.
CA2007643A1 (fr) *	1989-02-01	1990-08-01	Donald S. Karanewsky	Combinaison d'un inhibiteur de hmg coa et d'un inhibiteur de squalene synthetase et methode pour abaisser le taux de cholesterol sanguin par l'utilisation de cette combinaison
CA2042526A1 (fr) *	1990-06-11	1991-12-12	Adeoye Y. Olukotun	Methode permettant de prevenir une deuxieme crise cardiaque a l'aide d'un inhibiteur de la hmg coa-reductase
US5202327A (en) *	1991-07-10	1993-04-13	E. R. Squibb & Sons, Inc.	Phosphorus-containing hmg-coa reductase inhibitors
GB9126144D0 (en) *	1991-12-10	1992-02-12	British Bio Technology	Compounds
US20010006644A1 (en)	1997-07-31	2001-07-05	David J. Bova	Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
EE200100155A (et)	1998-09-17	2002-08-15	Bristol-Myers Squibb Company	Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
DK1385856T3 (da)	2001-04-11	2006-05-15	Bristol Myers Squibb Co	Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
GEP20063908B (en)	2001-10-18	2006-08-25	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en)	2001-11-02	2004-10-19	Bristol-Myers Squibb Company	Process for the preparation of aniline-derived thyroid receptor ligands
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
ATE469645T1 (de)	2002-10-23	2010-06-15	Bristol Myers Squibb Co	Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7098235B2 (en)	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en)	2003-01-24	2005-02-01	Bristol Myers Squibb Co	Substituted anilide ligands for the thyroid receptor
US7459474B2 (en)	2003-06-11	2008-12-02	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
US6995183B2 (en)	2003-08-01	2006-02-07	Bristol Myers Squibb Company	Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US8158362B2 (en)	2005-03-30	2012-04-17	Decode Genetics Ehf.	Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
PT1725234E (pt)	2004-03-05	2013-03-04	Univ Pennsylvania	Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
TW200611704A (en)	2004-07-02	2006-04-16	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en)	2004-07-02	2006-12-05	Bristol-Myers Squibb Co.	Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en)	2004-07-02	2009-05-19	Bristol-Myers Squibb Company	Sustained release GLP-1 receptor modulators
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en)	2004-12-29	2009-12-22	Bristol-Myers Squibb Company	Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en)	2004-12-29	2009-09-15	Bristol-Myers Squibb Company	Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076597A1 (fr)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Heterocycles bicycliques constituant des modulateurs des recepteurs cannabinoides
US7220859B2 (en)	2005-01-12	2007-05-22	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en)	2005-01-12	2008-01-01	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en)	2005-01-18	2006-07-20	Chongqing Sun	Bicyclic heterocycles as cannabinoid receptor modulators
EP1879881A2 (fr)	2005-04-14	2008-01-23	Bristol-Myers Squibb Company	Inhibiteurs de la 11-beta hydroxysteroide deshydrogenase de type i
US7521557B2 (en)	2005-05-20	2009-04-21	Bristol-Myers Squibb Company	Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en)	2005-06-17	2008-01-08	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en)	2005-06-17	2007-07-16	Bristol Myers Squibb Co	Triazolopyridine cannabinoid receptor 1 antagonists
US7629342B2 (en)	2005-06-17	2009-12-08	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
US8618115B2 (en)	2005-10-26	2013-12-31	Bristol-Myers Squibb Company	Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EP2487154B1 (fr)	2005-10-31	2013-10-16	Bristol-Myers Squibb Company	Inhibiteurs de la dipeptidyl peptidase IV à base amide de bêta-amino de pyrrolidinyle et procédés
US7592461B2 (en)	2005-12-21	2009-09-22	Bristol-Myers Squibb Company	Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en)	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
EP2021014A1 (fr)	2006-05-26	2009-02-11	Brystol-Myers Squibb Company	Modulateurs des récepteurs de glp-1 à libération prolongée
US7919598B2 (en)	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
US7968577B2 (en)	2006-11-01	2011-06-28	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
TW200904405A (en)	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Pharmaceutical formulations containing an SGLT2 inhibitor
PE20090696A1 (es)	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
WO2009023059A2 (fr)	2007-06-01	2009-02-19	The Trustees Of Princeton University	Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes
US20090011994A1 (en)	2007-07-06	2009-01-08	Bristol-Myers Squibb Company	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN101808995A (zh)	2007-07-27	2010-08-18	百时美施贵宝公司	新颖的葡糖激酶激活剂及其使用方法
ES2499018T3 (es)	2007-09-20	2014-09-26	Irm Llc	Compuestos y composiciones como moduladores de la actividad de GPR119
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
KR20110135411A (ko)	2009-03-27	2011-12-16	브리스톨-마이어스 스큅 컴퍼니	Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
WO2011014520A2 (fr)	2009-07-29	2011-02-03	Irm Llc	Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
CA2774573A1 (fr)	2009-10-09	2011-04-14	Irm Llc	Composes et compositions comme modulateurs de l'activite de gpr119
CA3002948C (fr)	2009-11-13	2020-10-27	Astrazeneca Uk Limited	Formules de comprime a liberation immediate
BR112012011274A2 (pt)	2009-11-13	2016-04-12	Astrazeneca Uk Ltd	formulação de metformina de massa reduzida e sua combinação
CN102711739B (zh)	2009-11-13	2015-12-16	阿斯利康(瑞典)有限公司	双层片剂
US8394858B2 (en)	2009-12-03	2013-03-12	Novartis Ag	Cyclohexane derivatives and uses thereof
TWI562775B (en)	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
EP2558461B1 (fr)	2010-04-14	2015-12-02	Bristol-Myers Squibb Company	Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs
RU2596787C2 (ru)	2010-07-09	2016-09-10	БиЭйчВи ФАРМА, ИНК.	Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
US8697739B2 (en)	2010-07-29	2014-04-15	Novartis Ag	Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh)	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2014052619A1 (fr)	2012-09-27	2014-04-03	Irm Llc	Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
TR201908247T4 (tr)	2012-11-20	2019-06-21	Lexicon Pharmaceuticals Inc	Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
WO2015027021A1 (fr)	2013-08-22	2015-02-26	Bristol-Myers Squibb Company	Dérivés imide et acylurée utilisés comme modulateurs du récepteur de glucocorticoïdes
CN104610262B (zh) *	2013-11-01	2017-06-06	上海医药工业研究院	联苯类化合物、中间体、制备方法、药物组合物及其应用
KR20170138570A (ko)	2015-04-30	2017-12-15	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
JOP20210009A1 (ar)	2018-07-19	2021-01-12	Astrazeneca Ab	طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
KR20210065974A (ko)	2018-09-26	2021-06-04	렉시컨 파마슈티컬스 인코퍼레이티드	N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법
BR112023000808A2 (pt)	2020-07-29	2023-02-07	Amryt Pharmaceuticals Inc	Lomitapida para uso em métodos para tratar hiperlipidemia e hipercolesterolemia em pacientes pediátricos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA828650B (en) *	1981-12-01	1983-09-28	Hunt Chem Corp Philip A	Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof
FR2596393B1 (fr) *	1986-04-01	1988-06-03	Sanofi Sa	Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
ES2009919A6 (es) *	1987-05-22	1989-10-16	Squibb & Sons Inc	Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo y nuevos compuestos intermedios.

1988
- 1988-05-20 DK DK277488A patent/DK277488A/da not_active Application Discontinuation
- 1988-05-20 AU AU16508/88A patent/AU610591B2/en not_active Ceased
- 1988-05-20 GR GR880100331A patent/GR1000959B/el unknown
- 1988-05-20 IL IL86464A patent/IL86464A/xx not_active IP Right Cessation
- 1988-05-20 NO NO882218A patent/NO882218L/no unknown
- 1988-05-20 ES ES8801610A patent/ES2009918A6/es not_active Expired
- 1988-05-20 IE IE154388A patent/IE63760B1/en not_active IP Right Cessation
- 1988-05-20 FI FI882384A patent/FI89493C/fi not_active IP Right Cessation
- 1988-05-20 HU HU882614A patent/HU205125B/hu not_active IP Right Cessation
- 1988-05-20 IT IT20682/88A patent/IT1217685B/it active
- 1988-05-20 PT PT87539A patent/PT87539B/pt not_active IP Right Cessation
- 1988-05-20 IE IE930324A patent/IE930324L/xx unknown
- 1988-05-20 GB GB8811929A patent/GB2205837B/en not_active Expired - Fee Related
- 1988-05-20 NZ NZ224733A patent/NZ224733A/en unknown
- 1988-05-20 DE DE3817375A patent/DE3817375C2/de not_active Expired - Fee Related
- 1988-05-20 SE SE8801903A patent/SE503210C2/sv not_active IP Right Cessation
- 1988-05-20 PH PH36956A patent/PH25350A/en unknown
- 1988-05-21 JP JP63124809A patent/JP2680347B2/ja not_active Expired - Lifetime
- 1988-05-21 PL PL1988272597A patent/PL154877B1/pl unknown
- 1988-05-21 CN CN198888103091A patent/CN88103091A/zh active Pending
- 1988-05-21 KR KR1019880006020A patent/KR880013958A/ko not_active Ceased
- 1988-05-24 BE BE8800566A patent/BE1004193A3/fr not_active IP Right Cessation
- 1988-05-24 CH CH1967/88A patent/CH676984A5/fr not_active IP Right Cessation
- 1988-05-24 NL NL8801330A patent/NL8801330A/nl not_active Application Discontinuation
- 1988-05-24 FR FR8806885A patent/FR2615508B1/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IT8820682A0 (it)	1988-05-20
FI882384A7 (fi)	1988-11-23
NO882218D0 (no)	1988-05-20
IE930324L (en)	1988-11-22
HU205125B (en)	1992-03-30
JP2680347B2 (ja)	1997-11-19
SE8801903L (sv)	1988-11-23
CN88103091A (zh)	1988-12-21
DK277488A (da)	1988-11-23
DE3817375C2 (de)	1997-04-30
GB2205837A (en)	1988-12-21
PH25350A (en)	1991-05-13
PL154877B1 (en)	1991-09-30
IL86464A (en)	1993-06-10
CH676984A5 (fr)	1991-03-28
IE881543L (en)	1988-11-22
AU1650888A (en)	1988-11-24
GB8811929D0 (en)	1988-06-22
ES2009918A6 (es)	1989-10-16
FI882384A0 (fi)	1988-05-20
PT87539A (pt)	1989-05-31
JPS6456689A (en)	1989-03-03
IE63760B1 (en)	1995-06-14
HUT49358A (en)	1989-09-28
GB2205837B (en)	1991-11-20
GR880100331A (en)	1989-02-23
PL272597A1 (en)	1989-03-06
NZ224733A (en)	1990-12-21
AU610591B2 (en)	1991-05-23
BE1004193A3 (fr)	1992-10-13
FI89493C (fi)	1993-10-11
NL8801330A (nl)	1988-12-16
DE3817375A1 (de)	1988-12-08
KR880013958A (ko)	1988-12-22
DK277488D0 (da)	1988-05-20
SE503210C2 (sv)	1996-04-22
IT1217685B (it)	1990-03-30
FR2615508A1 (fr)	1988-11-25
FI89493B (fi)	1993-06-30
SE8801903D0 (sv)	1988-05-20
GR1000959B (el)	1993-03-16
FR2615508B1 (fr)	1994-11-25
IL86464A0 (en)	1988-11-15
PT87539B (pt)	1992-09-30

Publication	Publication Date	Title
NO882218D0 (no)	1988-05-20	Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
NO860371L (no)	1986-08-05	Fremgangsmaate ved fremstilling av peptidaseinhibitorer.
NO885605D0 (no)	1988-12-16	Fremgangsmaate for fremstilling av smoereolje.
DE3681991D1 (de)	1991-11-21	Hmg-coa-reduktase-hemmungskoerper.
NO882219D0 (no)	1988-05-20	Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
NO170071C (no)	1992-09-09	Fremgangsmaate ved fremstilling av klordioksyd.
NO880262D0 (no)	1988-01-22	Fremgangsmaate for fremstilling av b avermectiner.
NO880068D0 (no)	1988-01-08	Fremgangsmaate ved fremstilling av heteroaryl-3-okso-propannitrilderivater.
NO872356D0 (no)	1987-06-04	Fremgangsmaate til fremstilling av monokaliumfosfat.
NO884665L (no)	1989-04-24	Fremgangsmaate ved fremstilling av 9-oh-alkoksyguanin.
PT88364A (pt)	1989-07-31	Process for preparing novel hmg-coa reductase inhibitors
NO883145L (no)	1989-01-16	Fremgangsmaate til fremstilling av tienoimidazol-derivater.
NO170022C (no)	1992-09-02	Fremgangsmaate for fremstilling av sialocylglycerolipider.
NO882730D0 (no)	1988-06-21	Fremgangsmaate for fremstilling av aminocyklopentyletere.
NO901422L (no)	1990-10-01	Fremgangsmaate for fremstilling av alfa-glucosidase-inhibitorer.
NO881055L (no)	1988-09-12	Fremgangsmaate ved fremstilling av okso-isoindolinyl-derivater.
NO880106L (no)	1988-08-19	Fremgangsmaate til fremstilling av kalknitrogen.
NO883610L (no)	1989-02-16	Fremgangsmaate til fremstilling av substituerte tienoimidazol-derivater.
NO880834L (no)	1988-08-29	Fremgangsmaate for fremstilling av heterocyclyl-2-propyn-1-aminer.
NO883398D0 (no)	1988-08-01	Fremgangsmaate for fremstilling av benzoksazinderivater.
NO872355L (no)	1987-12-07	Fremgangsmaate til fremstilling av monokaliumfosfat.
NO892761D0 (no)	1989-07-04	Fremgangsmaate for fremstilling av inhibitorer for 3-keto-hmg-coa-reduktase.
NO913089D0 (no)	1991-08-08	Fremgangsmaate for fremstilling av tetrazolforbindelser.
NO890375D0 (no)	1989-01-30	Fremgangsmaate for fremstilling av heksanitrostilben.
NO880844D0 (no)	1988-02-26	Fremgangsmaate for fremstilling av cytotoksiner.